Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Healthcare Industry News Thermo Fisher raises $2.5bn in bonds—But what’s the bigger play behind the debt move? Thermo Fisher Scientific priced $2.5B in senior notes to fuel acquisitions, refinancing, and growth. See how the deal shapes TMO’s 2026 outlook. byPallavi MadhirajuOctober 1, 2025